[Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma].

Xia, Y X; Cao, H S; Tang, W W; Wang, X H

Xia, Y X; Cao, H S; Tang, W W; Wang, X H.

Afiliação

Xia YX; Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,National Health Commission Key Laboratory of Living Donor Liver Transplantation,Nanjing Medical University,Nanjing 210000,China.
Cao HS; Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,National Health Commission Key Laboratory of Living Donor Liver Transplantation,Nanjing Medical University,Nanjing 210000,China.
Tang WW; Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,National Health Commission Key Laboratory of Living Donor Liver Transplantation,Nanjing Medical University,Nanjing 210000,China.
Wang XH; Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University,Key Laboratory of Liver Transplantation,Chinese Academy of Medical Sciences,National Health Commission Key Laboratory of Living Donor Liver Transplantation,Nanjing Medical University,Nanjing 210000,China.

Zhonghua Wai Ke Za Zhi ; 61(1): 7-12, 2023 Jan 01.

Article em Zh | MEDLINE | ID: mdl-36603877

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Humanos; Carcinoma Hepatocelular/patologia; Terapia Neoadjuvante; Neoplasias Hepáticas/patologia; Imunoterapia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google